DK2914627T3 - Anti-cd40-antistoffer og fremgangsmåder til anvendelse - Google Patents
Anti-cd40-antistoffer og fremgangsmåder til anvendelse Download PDFInfo
- Publication number
- DK2914627T3 DK2914627T3 DK13786884.0T DK13786884T DK2914627T3 DK 2914627 T3 DK2914627 T3 DK 2914627T3 DK 13786884 T DK13786884 T DK 13786884T DK 2914627 T3 DK2914627 T3 DK 2914627T3
- Authority
- DK
- Denmark
- Prior art keywords
- antibodies
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- H—ELECTRICITY
- H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
- H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
- H05K999/00—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group
- H05K999/99—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS dummy group dummy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261720289P | 2012-10-30 | 2012-10-30 | |
| PCT/US2013/067583 WO2014070934A1 (en) | 2012-10-30 | 2013-10-30 | Anti-cd40 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2914627T3 true DK2914627T3 (da) | 2021-07-12 |
Family
ID=49551838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK13786884.0T DK2914627T3 (da) | 2012-10-30 | 2013-10-30 | Anti-cd40-antistoffer og fremgangsmåder til anvendelse |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US9676861B2 (da) |
| EP (2) | EP2914627B1 (da) |
| JP (4) | JP6693745B2 (da) |
| KR (1) | KR102270618B1 (da) |
| CN (3) | CN110066335B (da) |
| AU (2) | AU2013337903B2 (da) |
| CA (1) | CA2888763A1 (da) |
| DK (1) | DK2914627T3 (da) |
| ES (1) | ES2879552T3 (da) |
| HK (1) | HK1213581A1 (da) |
| NZ (1) | NZ707086A (da) |
| WO (1) | WO2014070934A1 (da) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102002104A (zh) | 2009-08-28 | 2011-04-06 | 江苏先声药物研究有限公司 | 一种抗vegf的单克隆抗体及含有该抗体的药物组合物 |
| WO2012048113A2 (en) | 2010-10-07 | 2012-04-12 | The General Hospital Corporation | Biomarkers of cancer |
| JP6125489B2 (ja) | 2011-04-29 | 2017-05-10 | アペクシジェン， インコーポレイテッド | 抗ｃｄ４０抗体および使用方法 |
| US9676861B2 (en) | 2012-10-30 | 2017-06-13 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| CN105693845B (zh) * | 2014-11-24 | 2020-10-02 | 中国科学院上海营养与健康研究所 | 一种cd40胞外区的表达纯化及其用途 |
| PE20180193A1 (es) | 2015-05-29 | 2018-01-26 | Abbvie Inc | Anticuerpos anti-cd40 y sus usos |
| CN115887671A (zh) | 2015-07-16 | 2023-04-04 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| CN108368510B (zh) | 2015-09-30 | 2023-09-01 | 詹森生物科技公司 | 特异性结合人cd40的激动性抗体和使用方法 |
| MA43186B1 (fr) | 2015-11-03 | 2022-03-31 | Janssen Biotech Inc | Anticorps se liant spécifiquement à pd-1 et leurs utilisations |
| EP3423489A1 (en) * | 2016-03-04 | 2019-01-09 | The Rockefeller University | Antibodies to cd40 with enhanced agonist activity |
| BR112018071307A2 (pt) | 2016-04-18 | 2019-02-26 | Celldex Therapeutics, Inc. | anticorpos agonistas que ligam cd40 humana e usos dos mesmos |
| SG11201810591VA (en) | 2016-05-27 | 2018-12-28 | Abbvie Biotherapeutics Inc | Bispecific binding proteins binding an immunomodulatory protein and a tumor antigen |
| UA123111C2 (uk) | 2016-05-27 | 2021-02-17 | Еббві Байотерапьютікс Інк. | Антитіло до cd40 та його застосування |
| WO2017214452A1 (en) | 2016-06-08 | 2017-12-14 | Xencor, Inc. | Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b |
| WO2017211321A1 (zh) * | 2016-06-08 | 2017-12-14 | 上海交通大学医学院 | 增强激动型抗体活性的抗体重链恒定区序列 |
| MX2018016364A (es) | 2016-06-20 | 2019-11-28 | Kymab Ltd | Anticuerpos anti-pd-l1. |
| KR102632202B1 (ko) | 2016-07-14 | 2024-02-02 | 젠맵 에이/에스 | Cd40 및 cd137에 대한 다중특이적 항체 |
| WO2018031400A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| KR102587941B1 (ko) | 2016-08-12 | 2023-10-11 | 얀센 바이오테크 인코포레이티드 | 향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자 |
| CN110114089A (zh) * | 2016-11-02 | 2019-08-09 | 埃派斯进有限公司 | 组合中的抗cd40抗体及其使用方法 |
| WO2018089688A1 (en) | 2016-11-09 | 2018-05-17 | Jinjun Shi | Restoration of tumor suppression using mrna-based delivery system |
| CN110382541A (zh) * | 2017-03-29 | 2019-10-25 | 葛莱高托普有限公司 | 人源化抗cd40抗体 |
| TWI788340B (zh) * | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| JP7257971B6 (ja) * | 2017-06-01 | 2023-07-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 |
| CN109136274B (zh) | 2017-06-19 | 2021-04-23 | 百奥赛图江苏基因生物技术有限公司 | 人源化cd40基因改造动物模型的制备方法及应用 |
| WO2018233607A1 (en) * | 2017-06-19 | 2018-12-27 | Beijing Biocytogen Co., Ltd | NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH HUMAN OR CHIMERIC CD40 |
| CN109384845B (zh) * | 2017-08-14 | 2022-06-21 | 中国科学院上海营养与健康研究所 | 一种cd40单克隆抗体、其制备方法及其应用 |
| EP3740509A4 (en) | 2018-01-17 | 2022-06-22 | Apexigen, Inc. | ANTI-PD-L1 ANTIBODIES AND METHODS OF USE |
| CA3090652A1 (en) | 2018-02-06 | 2019-08-15 | The General Hospital Corporation | Repeat rna as biomarkers of tumor immune response |
| US20210179727A1 (en) * | 2018-04-20 | 2021-06-17 | Lyvgen Biopharma Co., Ltd. | Anti-cd40 antibodies and uses thereof |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| AR117091A1 (es) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| CN113226357A (zh) | 2018-11-23 | 2021-08-06 | 斯特赖克药物公司 | 双特异性缀合物 |
| TW202039558A (zh) | 2018-11-30 | 2020-11-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途 |
| EP3939998A4 (en) | 2018-11-30 | 2022-08-10 | Jiangsu Hengrui Medicine Co., Ltd. | PHARMACEUTICAL COMPOSITION WITH CD40 ANTIBODY AND USE THEREOF |
| CN109678959B (zh) * | 2019-02-22 | 2020-12-08 | 北京免疫方舟医药科技有限公司 | 抗cd40抗体及其应用 |
| CN111454362B (zh) * | 2019-03-04 | 2021-03-02 | 北京天广实生物技术股份有限公司 | 特异结合cd40的抗体及其用途 |
| US10570210B1 (en) | 2019-03-04 | 2020-02-25 | Beijing Mabworks Biotech Co.Ltd | Antibodies binding CD40 and uses thereof |
| US20220324988A1 (en) * | 2019-04-10 | 2022-10-13 | Nankai University | Anti-CD40 antibodies and uses thereof |
| EP3962493A2 (en) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor |
| EP4027998A1 (en) | 2019-09-09 | 2022-07-20 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| WO2021048595A1 (en) * | 2019-09-11 | 2021-03-18 | Novartis Ag | A method for preventing human virus associated disorders in patients |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| GB202008003D0 (en) | 2020-05-28 | 2020-07-15 | Quine Medical Ab | Anti-CD40 antibody |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| WO2022002065A1 (zh) * | 2020-06-30 | 2022-01-06 | 百奥泰生物制药股份有限公司 | 抗cd40抗体或抗原结合片段及其应用 |
| WO2022212784A1 (en) | 2021-03-31 | 2022-10-06 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| CA3224374A1 (en) | 2021-06-29 | 2023-01-05 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023046131A1 (zh) * | 2021-09-26 | 2023-03-30 | 正大天晴药业集团股份有限公司 | 抗cd40抗体的应用 |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
Family Cites Families (114)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
| US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
| US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
| US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
| JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
| JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
| JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
| JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
| US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
| JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
| JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
| EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
| US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
| US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
| US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
| JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| US5247069A (en) | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever Nv | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| DE69433406T2 (de) | 1993-10-01 | 2004-10-07 | Immunex Corp | Antikörper gegen cd40 |
| ATE267607T1 (de) * | 1993-12-23 | 2004-06-15 | Immunex Corp | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| GB9425060D0 (en) | 1994-12-13 | 1995-02-08 | Univ Birmingham | Carcinoma treatment |
| US5675063A (en) | 1995-02-28 | 1997-10-07 | Loyola University Of Chicago | Immortalized rabbit hybridoma fusion partner |
| AU699291B2 (en) | 1995-03-01 | 1998-11-26 | Immunex Corporation | Method for stimulating an immune response |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| EP1033406A4 (en) * | 1997-10-27 | 2005-03-09 | Sumitomo Electric Industries | INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| KR100301796B1 (ko) * | 1998-10-01 | 2001-09-06 | 성재갑 | 면역억제능이 있는 항-씨디40 리간드 모노클로날 항체 |
| US6680176B2 (en) | 1999-05-17 | 2004-01-20 | The United States Of America, As Represented By The Department Of Health And Human Services | Identification of candidate ligands which modulate antigen presenting cells |
| US20030118588A1 (en) | 1999-05-22 | 2003-06-26 | Linda Diehl | Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40 |
| US6946129B1 (en) | 1999-06-08 | 2005-09-20 | Seattle Genetics, Inc. | Recombinant anti-CD40 antibody and uses thereof |
| AU2001236621B2 (en) | 2000-02-01 | 2006-06-15 | Mycenax Biotech Inc. | Cd40-binding apc-activating molecules |
| MXPA02010147A (es) * | 2000-04-19 | 2003-10-15 | Tanox Inc | Antagonistas cd40 para uso en el tratamiento de psoriasis y otras condiciones inflamatorias de la piel. |
| US7063845B2 (en) | 2000-04-28 | 2006-06-20 | Gemini Science, Inc. | Human anti-CD40 antibodies |
| IL152652A0 (en) | 2000-05-08 | 2003-06-24 | Medarex Inc | Human monoclonal antibodies to dendritic cells |
| JP4025881B2 (ja) * | 2001-04-27 | 2007-12-26 | キリンファーマ株式会社 | 抗ｃｄ４０モノクローナル抗体 |
| CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US20080199471A1 (en) | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| US7662925B2 (en) | 2002-03-01 | 2010-02-16 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| ES2349777T3 (es) * | 2003-01-22 | 2011-01-11 | Glycart Biotechnology Ag | Constructos de fusión y uso de los mismos para producir anticuerpos con mayor afinidad de unión al receptor de fc y función efectora. |
| CN1905897B (zh) * | 2003-11-04 | 2012-09-05 | 诺华疫苗和诊断公司 | 拮抗性抗-cd40单克隆抗体和它们的使用方法 |
| EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| US20050136055A1 (en) | 2003-12-22 | 2005-06-23 | Pfizer Inc | CD40 antibody formulation and methods |
| US8568725B2 (en) * | 2003-12-25 | 2013-10-29 | Kyowa Hakko Kirin Co., Ltd. | Method of treating transplant rejection with an anti-CD40 antibody |
| BR122018016031B8 (pt) | 2004-08-04 | 2021-07-27 | Applied Molecular Evolution Inc | processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| CA2595682A1 (en) | 2005-01-31 | 2006-08-03 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
| US20060257359A1 (en) | 2005-02-28 | 2006-11-16 | Cedric Francois | Modifying macrophage phenotype for treatment of disease |
| EP1871808A2 (en) | 2005-03-31 | 2008-01-02 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| JP5208730B2 (ja) | 2005-05-18 | 2013-06-12 | ノバルティス アーゲー | Ｃｄ４０シグナル伝達によって媒介される増殖性障害の診断および治療のための方法 |
| ES2429564T3 (es) | 2005-05-18 | 2013-11-15 | Novartis Ag | Procedimientos para el diagnóstico y tratamiento de enfermedades que tienen un componente autoinmune y/o inflamatorio |
| KR100991010B1 (ko) | 2005-05-26 | 2010-10-29 | 제넨테크, 인크. | 인간화 항-ｃｄ４０ 항체 및 그의 사용 방법 |
| US7429487B2 (en) | 2005-07-05 | 2008-09-30 | Epitomics, Inc. | Fusion partner for production of monoclonal rabbit antibodies |
| AU2006308606C1 (en) * | 2005-11-01 | 2013-07-25 | Novartis Ag | Uses of anti-CD40 antibodies |
| US20090202531A1 (en) | 2005-11-01 | 2009-08-13 | Novartis Ag | Uses of anti-cd40 antibodies |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| EP1968636A4 (en) | 2005-12-09 | 2010-06-02 | Seattle Genetics Inc | METHOD OF USE OF CD40 BONDING AGENTS |
| CA2669412A1 (en) * | 2007-01-23 | 2008-07-31 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US20090238825A1 (en) | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| WO2008144757A1 (en) | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| EP2176298B1 (en) | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| WO2009094391A1 (en) | 2008-01-23 | 2009-07-30 | Xencor, Inc. | Optimized cd40 antibodies and methods of using the same |
| JP5984388B2 (ja) | 2008-07-16 | 2016-09-06 | ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ | 最大限のｇａｇ及びｎｅｆを樹状細胞に対して標的化することに基づくｈｉｖワクチン |
| CN102170908A (zh) | 2008-08-29 | 2011-08-31 | 莱顿大学医学中心附属莱顿教学医院 | 向个体的肿瘤引流淋巴结递送cd40激动剂 |
| DK2367849T3 (da) | 2008-12-05 | 2018-01-22 | Als Therapy Development Inst | Fremgangsmåde til behandling af neurodegenerative sygdomme |
| DK2406286T3 (da) | 2009-03-10 | 2016-08-22 | Baylor Res Inst | Anti-cd40-antistoffer og anvendelser deraf |
| KR101787768B1 (ko) | 2009-04-18 | 2017-10-18 | 제넨테크, 인크. | 항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법 |
| CA2759146C (en) | 2009-04-20 | 2017-06-13 | Kyowa Hakko Kirin Co., Ltd. | Agonist anti-cd40 antibody |
| CA2794708C (en) * | 2010-03-29 | 2021-11-16 | Zymeworks Inc. | Antibodies with enhanced or suppressed effector function |
| LT3178851T (lt) | 2010-03-31 | 2020-08-10 | Boehringer Ingelheim International Gmbh | Anti-cd40 antikūnai |
| WO2012019041A2 (en) | 2010-08-04 | 2012-02-09 | Duke University | Regulatory b cells and their uses |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| AU2011349502B2 (en) | 2010-12-20 | 2016-12-22 | The Rockefeller University | Modulating agonistic TNFR antibodies |
| CA2833743A1 (en) * | 2011-04-21 | 2012-10-26 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize cd40 |
| JP6125489B2 (ja) | 2011-04-29 | 2017-05-10 | アペクシジェン， インコーポレイテッド | 抗ｃｄ４０抗体および使用方法 |
| US9676861B2 (en) | 2012-10-30 | 2017-06-13 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
-
2013
- 2013-10-30 US US14/067,770 patent/US9676861B2/en active Active
- 2013-10-30 JP JP2015539949A patent/JP6693745B2/ja active Active
- 2013-10-30 NZ NZ707086A patent/NZ707086A/en unknown
- 2013-10-30 EP EP13786884.0A patent/EP2914627B1/en active Active
- 2013-10-30 CN CN201811214790.8A patent/CN110066335B/zh active Active
- 2013-10-30 CN CN201380068690.8A patent/CN104918957B/zh active Active
- 2013-10-30 EP EP21166914.8A patent/EP3925977A1/en active Pending
- 2013-10-30 AU AU2013337903A patent/AU2013337903B2/en active Active
- 2013-10-30 CA CA2888763A patent/CA2888763A1/en active Pending
- 2013-10-30 ES ES13786884T patent/ES2879552T3/es active Active
- 2013-10-30 CN CN201811214473.6A patent/CN109265552A/zh active Pending
- 2013-10-30 WO PCT/US2013/067583 patent/WO2014070934A1/en active Application Filing
- 2013-10-30 KR KR1020157013665A patent/KR102270618B1/ko active IP Right Grant
- 2013-10-30 DK DK13786884.0T patent/DK2914627T3/da active
-
2016
- 2016-02-12 HK HK16101574.4A patent/HK1213581A1/zh unknown
-
2017
- 2017-05-12 US US15/594,367 patent/US9994640B2/en active Active
-
2018
- 2018-03-13 US US15/920,197 patent/US20180273630A1/en not_active Abandoned
- 2018-08-06 JP JP2018147573A patent/JP2018166522A/ja not_active Withdrawn
- 2018-11-02 AU AU2018256638A patent/AU2018256638B2/en active Active
-
2020
- 2020-08-21 JP JP2020139887A patent/JP2020195388A/ja not_active Withdrawn
-
2021
- 2021-04-15 US US17/231,483 patent/US20220049006A1/en not_active Abandoned
-
2022
- 2022-10-11 JP JP2022163062A patent/JP2022191360A/ja active Pending
-
2023
- 2023-03-13 US US18/182,827 patent/US20230406948A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN104918957B (zh) | 2018-11-16 |
| CN104918957A (zh) | 2015-09-16 |
| WO2014070934A1 (en) | 2014-05-08 |
| CN110066335A (zh) | 2019-07-30 |
| US20230406948A1 (en) | 2023-12-21 |
| US20140120103A1 (en) | 2014-05-01 |
| EP2914627B1 (en) | 2021-04-07 |
| JP2020195388A (ja) | 2020-12-10 |
| US20170246297A1 (en) | 2017-08-31 |
| US9676861B2 (en) | 2017-06-13 |
| CA2888763A1 (en) | 2014-05-08 |
| NZ707086A (en) | 2019-07-26 |
| EP3925977A1 (en) | 2021-12-22 |
| HK1213581A1 (zh) | 2016-07-08 |
| CN109265552A (zh) | 2019-01-25 |
| JP2018166522A (ja) | 2018-11-01 |
| JP2015533853A (ja) | 2015-11-26 |
| EP2914627A1 (en) | 2015-09-09 |
| JP2022191360A (ja) | 2022-12-27 |
| US20180273630A1 (en) | 2018-09-27 |
| US20220049006A1 (en) | 2022-02-17 |
| AU2018256638A1 (en) | 2018-11-29 |
| US9994640B2 (en) | 2018-06-12 |
| JP6693745B2 (ja) | 2020-05-13 |
| KR102270618B1 (ko) | 2021-06-30 |
| KR20150079787A (ko) | 2015-07-08 |
| ES2879552T3 (es) | 2021-11-22 |
| AU2018256638B2 (en) | 2020-09-10 |
| AU2013337903A1 (en) | 2015-05-07 |
| AU2013337903B2 (en) | 2018-08-16 |
| CN110066335B (zh) | 2024-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2914627T3 (da) | Anti-cd40-antistoffer og fremgangsmåder til anvendelse | |
| IL280155A (en) | Anti- SIGLEC-8 antibodies and methods of using them | |
| DK3083689T3 (da) | Anti-CD3-antistoffer og fremgangsmåder til anvendelse | |
| DK2675827T3 (da) | Hidtil ukendte modulatorer og fremgangsmåder til anvendelse | |
| ZA201603308B (en) | Novel anti-claudin antibodies and methods of use | |
| DK2900657T3 (da) | Cykliske etherpyrazol-4-yl-heterocyclyl-carboxamidforbindelser og fremgangsmåder til anvendelse | |
| HK1212256A1 (en) | Anti-mcam antibodies and associated methods of use -mcam | |
| DK3556774T3 (da) | Anti-CD40-antistoffer og anvendelser deraf | |
| DK2961831T3 (da) | Sammensætninger og fremgangsmåder til immunterapi | |
| DK2929031T5 (da) | Pcsk9-irna-sammensætninger og fremgangsmåder til anvendelse deraf | |
| DK3086807T3 (da) | Antistoffer og fremgangsmåder til anvendelse | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| HUE051982T2 (hu) | Anti-alfa-szinuklein antitestek és alkalmazási eljárások | |
| IL245946A0 (en) | Anti-dpep3 antibodies and methods of use | |
| IL238227A0 (en) | Antibodies against c16orf54 and uses thereof | |
| DK2683731T3 (da) | C4-monomethyl-triterpenoidderivater og fremgangsmåder til anvendelse deraf | |
| DK2806892T3 (da) | Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser | |
| HK1225612A1 (zh) | 抗ly6e抗體及使用方法 | |
| ZA201404675B (en) | Anti-lrp5 antibodies and methods of use | |
| EP2734234A4 (en) | ANTI-CXCR4 ANTIBODIES AND METHOD OF USE THEREOF | |
| DK3453723T3 (da) | Anti-ASIC1-antistoffer og anvendelser deraf | |
| EP2938632A4 (en) | ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE | |
| HK1209432A1 (en) | Anti-jagged antibodies and methods of use | |
| DK2882863T3 (da) | System og fremgangsmåde til kvantitativ billeddannelse af mitokondriekompleks 1 | |
| DK2920204T3 (da) | Streptavidinmuteiner og fremgangsmåder til anvendelse deraf |